WallStSmart

Abbott Laboratories (ABT)vsCarMax Inc (KMX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 63% more annual revenue ($45.13B vs $27.76B). ABT leads profitability with a 13.9% profit margin vs 0.9%. KMX appears more attractively valued with a PEG of 0.38. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

KMX

Buy

52

out of 100

Grade: C-

Growth: 2.0Profit: 4.0Value: 8.7Quality: 4.5
Piotroski: 3/9Altman Z: 1.53
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$87.55

Current Price

$84.32

$3.23 discount

UndervaluedFair: $87.55Overvalued
KMXUndervalued (+83.0%)

Margin of Safety

+83.0%

Fair Value

$270.07

Current Price

$40.34

$229.73 discount

UndervaluedFair: $270.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

KMX2 strengths · Avg: 10.0/10
PEG RatioValuation
0.3810/10

Growing faster than its price suggests

Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

KMX4 concerns · Avg: 3.3/10
Altman Z-ScoreHealth
1.534/10

Distress zone — elevated risk

Return on EquityProfitability
4.1%3/10

ROE of 4.1% — below average capital efficiency

Profit MarginProfitability
0.9%3/10

0.9% margin — thin

Operating MarginProfitability
1.8%3/10

Operating margin of 1.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : KMX

The strongest argument for KMX centers on PEG Ratio, Price/Book. PEG of 0.38 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : KMX

The primary concerns for KMX are Altman Z-Score, Return on Equity, Profit Margin. Debt-to-equity of 2.75 is elevated, increasing financial risk. Thin 0.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

KMX carries more volatility with a beta of 1.18 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (56/100 vs 52/100). KMX offers better value entry with a 83.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

CarMax Inc

CONSUMER CYCLICAL · AUTO & TRUCK DEALERSHIPS · USA

CarMax is a used vehicle retailer based in the United States. It operates two business segments: CarMax Sales Operations and CarMax Auto Finance.

Visit Website →

Want to dig deeper into these stocks?